BioLife Solutions (BLFS) Q4 2025 earnings summary

Executive summary

• Achieved double-digit revenue growth, operating margin expansion, and improved profitability in 2025, driven by strategic transformation and portfolio optimization.

• Achieved fourth quarter 2025 revenue of $24.8 million, up 20% year-over-year; full year 2025 revenue reached $96.2 million, up 29% year-over-year.

• Divested evo product line/subsidiary, resulting in a simpler, more focused business with a strong balance sheet and $25.5 million in cash proceeds.

• BPM products embedded in 16 approved therapies and used in over 250 CGT trials, maintaining a 70%+ market share.

Financial highlights

• Full year 2025 revenue grew 29% year-over-year to $96.2 million, at the high end of guidance.

• Q4 2025 revenue was $24.8 million, up 20% year-over-year.

• Adjusted EBITDA for 2025 was $25 million (26% of revenue), up from $13 million (18%) in 2024.

• Adjusted net income for 2025 was $6.3 million, compared to a net loss of $2.9 million in 2024.

• Adjusted gross margin for 2025 was 66%, down from 69% in 2024, due to product mix and lower bag yields.

Outlook and guidance

• 2026 revenue guidance is $112.5–$115 million, representing 17–20% growth.

• Expecting full year positive GAAP net income for the first time in many years.

• Gross margins expected to remain in the mid-sixties, with further adjusted EBITDA margin expansion.

• Growth in 2026 primarily driven by commercial customers, with commercial mix expected to reach 50–55%.